JW생명과학

234080KOSPI의약품 제조업

57.5 / 100

Reference Date: 2026-07-24

Financial Score30.0 / 40

News Sentiment12.5 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Operating Profit metrics are weak. Slightly up 1.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Life Science achieved sales of approximately 22.12 billion KRW in its 31st fiscal year, with its subsidiary JW Chungwa Pharmaceutical accounting for over 75.5% of total revenue. Through an exclusive licensing agreement with U.S.-based Baxter and EU-GMP certification for TPN production, the company is expanding its global IV solution market. Key products include basic, special, nutritional, and TPN IV solutions, with growth driven by overseas exports and B2B market expansion.

Number of Employees

319people

Average Salary

68.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

6.06Industry Average 11.236.5Point

Lower than industry avg (good)

PBR

0.80Industry Average 0.814.0Point

In line with industry avg

ROE

13.59Industry Average 4.017.0Point

3.4x industry avg (excellent)

Debt Ratio

5.98Industry Average 12.436.5Point

Half of industry avg (excellent)

Trend 2023~20256.0 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲11.7% (2-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲4.5% (2-year basis)

ROE Trend

2.5 / 4

Avg ROE 18.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (7%, downtrend)

Current 11,190Won52-week high 15,50052-week low 10,860

1-month return3.0Point

1m 1.54% (flat)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral주식등의대량보유상황보고서(약식)2026-07-10